These ADCs, which consist of a humanized anti-HER2 mAb linked to cytotoxic agents, can effectively target tumor cells with low levels of HER2 expression and exert cytotoxic effects on neighboring tumor cells via a bystander effect [72]. The gene discussed is ERBB2; the disease is neoplasm.